HIV Vaccines

SynCon^® HIV vaccines

Human immunodeficiency virus (HIV) is a retrovirus that causes acquired immunodeficiency syndrome (AIDS), a condition in humans in which progressive failure of the immune system allows life-threatening opportunistic infections and cancers to thrive. HIV is divided into two distinct types, HIV-1 and HIV-2, which display biological and clinical distinctions. Most HIV research focuses on
type 1.

There are six HIV-1 subtypes, or clades: A, B, C, D, E and AE; they tend to be geographically oriented. Inovio’s strategy is to advance HIV synthetic vaccines pertinent to distinct geographic areas through multiple collaborations to fund and conduct relevant clinical studies, as shown in the table below.

Inovio’s vaccines are unique in being able to generate both preventive and therapeutic immune responses.

Candidate	Geographic Focus	Target Envelope Clades	Target Antigens	Collaborator
PENNVAX®-B	North America Western Europe	Clade B	Gag, pol, env	Prophylactic study: HIV Vaccine Trials Network (HVTN) Therapeutic study: U. of Pennsylvania
PENNVAX®-G	Developing regions of Africa and Asia	Clades A, C, D	Gag, pol	USMHRP/NIAID
PENNVAX®-GP	Developing regions of Africa and Asia	Clades A, C	Gag, env	NIH/NIAID